

**TEXAS STATE BOARD OF PHARMACY**

**ANNUAL FINANCIAL REPORT**

*For The Year Ended August 31, 2024*

**Daniel Carroll, Pharm.D., R.Ph.**  
**Executive Director**

## TABLE OF CONTENTS

I.	LETTER OF TRANSMITTAL	
II.	GENERAL PURPOSE FINANCIAL STATEMENTS	
	A. Combined Balance Sheet / Statement of Net Assets - Governmental Funds	2
	B. Combined Statement of Revenues, Expenditures and Changes in Fund Balances/ Statement of Activities - Governmental Funds	6
III.	NOTES TO THE FINANCIAL STATEMENTS	
	1. Summary of Significant Accounting Policies	10
	2. Capital Assets	14
	3. Deposits, Investments, & Repurchase Agreements	15
	4. Short Term Debt	16
	5. Summary of Long-Term Liabilities	16
	6. Bonded Indebtedness	16
	7. Derivative Instruments	16
	8. Leases	16
	9. Pension Plans	17
	10. Deferred Compensation	17
	11. Post Employment Health Care and Life Insurance Benefits	17
	12. Interfund Balances/Activities	17
	13. Continuance Subject to Review	18
	14. Adjustments to Fund Balances/Net Assets	18
	15. Contingencies and Commitments	18
	16. Subsequent Events	18
	17. Risk Management	18
	18. Management Discussion and Analysis (Material Changes to AFR)	18
	19. The Financial Reporting Entity	18
	20. Stewardship, Compliance and Accountability	18
	21. N/A	19
	22. Donor-Restricted Endowments	19
	23. Extraordinary and Special Items	19
	24. Disaggregation of Receivable and Payable Balances	19
	25. Termination Benefits	19
	26. Segment Information	19
	27. Service Concession Agreements	19
	28. Deferred Outflows of Resources & Deferred Inflows of Resources	19
	29. Trouble Debt Restructuring	19
	30. Non-Exchange Financial Guaranters	19
	31. Tax Abatements	19
	32. Fund Balances	19
IV.	COMBINING STATEMENTS	
	A. Exhibit A-1: Combining Balance Sheet - All General and Consolidated Funds	20
	B. Exhibit A-2: Combining Statement of Revenues, Expenditures, and Changes in Fund Balances - General and Consolidated Funds	22



## TEXAS STATE BOARD OF PHARMACY

---

---

November 1, 2024

Honorable Greg Abbott, Governor  
Honorable Glenn Hegar, Texas Comptroller  
Jerry McGinty, Director, Legislative Budget Board  
Lisa Collier, State Auditor

Dear Lady and Gentlemen:

We are pleased to submit the Annual Financial Report of the Texas State Board of Pharmacy for the year ended August 31, 2024, in compliance with TEX. GOV'T CODE ANN Section 2101.011 and in accordance with the requirements established by the Comptroller of Public Accounts.

Due to the statewide requirements embedded in Governmental Accounting Standards Board Statement No. 34, *Basic Financial Statements- and Management's Discussion and Analysis – for State and Local Governments*, the Comptroller of Public Accounts does not require the accompanying annual financial report to comply with all the requirements in this statement. The financial report will be considered for audit by the State Auditor as part of the audit of the State of Texas Comprehensive Annual Financial Report; therefore, an opinion has not been expressed on the financial statements and related information contained in this report.

If you have any questions, please contact Ann Driscoll at 512-305-8048.

Sincerely,

Daniel Carroll, Pharm.D., R.Ph.  
Executive Director/Secretary



UNAUDITED

<u>LONG-TERM LIABILITIES ADJUSTMENTS</u>	<u>OTHER ADJUSTMENTS</u>	<u>STATEMENT OF NET ASSETS</u>
\$	\$	\$
		1,000.00
		15,000.00
		653.00
		3,731,418.61
		0.00
		8,706.00
		91,704.44
		0.00
<u>0.00</u>	<u>0.00</u>	<u>3,848,482.05</u>
\$	\$	\$
		656,776.17
		(440,791.33)
		133,219.57
		(87,489.16)
		2,597,074.50
		<u>(1,298,537.25)</u>
<u>0.00</u>	<u>0.00</u>	<u>1,560,252.50</u>
<u>\$ 0.00</u>	<u>\$ 0.00</u>	<u>\$ 5,408,734.55</u>
\$	\$	\$
		175,997.66
		0.00
		653.00
		1,685,439.01
		96,598.04
18,751.94		18,751.94
653,623.62		653,623.62
394,511.34		394,511.34
<u>1,066,886.90</u>	<u>0.00</u>	<u>3,025,574.61</u>

UNAUDITED

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
 EXHIBIT I  
 COMBINED BALANCE SHEET/ STATEMENT OF NET ASSETS -  
 GOVERNMENTAL FUNDS  
 For the Year Ended August 31, 2024

	GOVERNMENTAL FUNDS GENERAL FUNDS (Exh A1)	CAPITAL ASSETS ADJUSTMENTS
Subscription Liability		
Employees' Compensable Leave		
Total Non-Current Liabilities	<u>0.00</u>	<u>0.00</u>
<b>TOTAL LIABILITIES</b>	<u>1,958,687.71</u>	<u>0.00</u>
Fund Financial Statements - Fund		
FUND BALANCES (DEFICITS):		
Reserved For:	\$	\$
Consumable Inventories	0.00	
Imprest Accounts	0.00	
Encumbrances	0.00	
Unreserved:		
Undesignated:		
Other Unreserved - Undesignated	<u>1,889,794.34</u>	<u>0.00</u>
<b>TOTAL FUND BALANCES</b>	<u>1,889,794.34</u>	<u>0.00</u>
<b>TOTAL LIABILITIES AND FUND BALANCES</b>	<u>\$ 3,848,482.05</u>	<u>\$ 0.00</u>
Government-wide Statement - Net Assets		
Net Assets:		
Invested in Capital Assets, Net of Related Debt		1,560,252.50
Unrestricted		
<b>Total Net Assets</b>		<u>\$ 1,560,252.50</u>

The accompanying notes to the financial statements are an integral part of this statement.

UNAUDITED

LONG-TERM LIABILITIES ADJUSTMENTS	OTHER ADJUSTMENTS	STATEMENT OF NET ASSETS
672,767.04		672,767.04
333,142.50		333,142.50
<u>1,005,909.54</u>	<u>0.00</u>	<u>1,005,909.54</u>
<u>2,072,796.44</u>	<u>0.00</u>	<u>4,031,484.15</u>
\$	\$	\$
		0.00
		0.00
		0.00
<u>0.00</u>	<u>0.00</u>	<u>1,889,794.34</u>
<u>0.00</u>	<u>0.00</u>	<u>1,889,794.34</u>
<u>\$ 2,072,796.44</u>	<u>\$ 0.00</u>	<u>\$ 5,921,278.49</u>
<u>(2,072,796.44)</u>		<u>(512,543.94)</u>
		\$ <u>0.00</u>
<u>\$ (2,072,796.44)</u>	<u>0.00</u>	<u>1,377,250.40</u>
		<u>\$ 5,408,734.55</u>

UNAUDITED

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
 EXHIBIT II  
 COMBINED STATEMENT OF REVENUES, EXPENDITURES & CHANGES IN FUND  
 BALANCES / STATEMENT OF ACTIVITIES - GOVERNMENTAL FUNDS  
 For the Year Ended August 31, 2024

	General Funds (Exh A2)	Capital Asset Adjustments
REVENUES:	\$	\$
Legislative Appropriations:		
Original Appropriations	14,602,780.00	
Additional Appropriations	1,821,745.25	
Licenses and Permits	880,183.21	
Interest, Dividend and Other Income	0.00	
Other Revenue	17,616.99	
Total Revenues	17,322,325.45	0.00
EXPENDITURES:		
Salaries and Wages	7,066,187.83	
Payroll Related Costs	1,920,972.69	
Professional Fees & Services	4,362,296.73	
Travel	77,800.43	
Materials and Supplies	164,611.54	
Communication and Utilities	123,577.00	
Repairs and Maintenance	56,230.68	
Rentals and Leases	19,931.84	
Printing and Reproduction	166,360.77	
Other Operating Expenditures	465,025.64	
Debt Service Principal Leases/SBITA	634,896.73	
Capital Outlay	81,871.95	(81,871.95)
Amortization Expense		649,268.61
Depreciation Expense		86,141.83
Total Expenditures	15,139,763.83	653,538.49
EXCESS OF REVENUES OVER EXPENDITURES	2,182,561.62	(653,538.49)
OTHER FINANCING SOURCES (USES):		
Operating Transfers Out	(165,914.93)	
Gain on Sale of Assets		10,133.93
Sale of Capital Assets	10,133.93	(10,133.93)
Debt Svc Principal - Leases/SBITA		
Increase in Obligations - Leases/ SBITA	0.00	
Legislative Transfers Out (Agy 364, Fd 0001)	(485,420.00)	
Total Other Financing Sources (Uses)	(641,201.00)	0.00
NET CHANGE IN FUND BALANCES/NET ASSETS	1,541,360.62	(653,538.49)



UNAUDITED

<u>Long-term Liabilities Adjustments</u>	<u>Statement of Activities</u>
\$	\$
	14,602,780.00
	1,821,745.25
	880,183.21
	0.00
	<u>17,616.99</u>
0.00	17,322,325.45
82,227.34	7,148,415.17
	1,920,972.69
	4,362,296.73
	77,800.43
	164,611.54
	123,577.00
	56,230.68
	19,931.84
	166,360.77
4,585.78	469,611.42
(634,896.73)	0.00
	0.00
	649,268.61
	<u>86,141.83</u>
(548,083.61)	15,245,218.71
548,083.61	2,077,106.74
	(165,914.93)
	10,133.93
	0.00
0.00	0.00
0.00	0.00
	<u>(485,420.00)</u>
0.00	(641,201.00)
<u>548,083.61</u>	<u>1,435,905.74</u>

UNAUDITED

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
 EXHIBIT II  
 COMBINED STATEMENT OF REVENUES, EXPENDITURES & CHANGES IN FUND  
 BALANCES / STATEMENT OF ACTIVITIES - GOVERNMENTAL FUNDS  
 For the Year Ended August 31, 2024

	General Funds (Exh A2)	<u>Capital Asset Adjustments</u>
FUND BALANCES - Beginning	882,895.03	
Restatements	0.00	
Fund Balances Beginning Restated	<u>882,895.03</u>	
Lapsed Appropriations	<u>(534,461.31)</u>	
FUND BALANCES - Ending	<u>\$ 1,889,794.34</u>	
Government-wide Statement - Net Assets		
Change in Net Assets		<u>(653,538.49)</u>
Net Assets Beginning		2,213,790.99
Adjustments to Beginning Net Assets		
Convert from Fund Balances to Net Assets		
Restatements		
Net Assets Beginning as Restated and Adjusted		<u>2,213,790.99</u>
Net Assets Ending		<u>\$ 1,560,252.50</u>

The accompanying notes to the financial statements are an integral part of this statement.

UNAUDITED

<u>Long-term Liabilities Adjustments</u>	<u>Statement of Activities</u>
	882,895.03
	<u>0.00</u>
	(534,461.31)
	\$ 1,784,339.46
<u>548,083.61</u>	
(2,620,880.05)	(407,089.06)
	0.00
<u>(2,620,880.05)</u>	<u>(407,089.06)</u>
\$ <u>(2,072,796.44)</u>	\$ <u>1,377,250.40</u>

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
NOTES TO THE FINANCIAL STATEMENTS

**NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

A. ENTITY

The Texas State Board of Pharmacy is an agency of the State of Texas and its financial records comply with state statutes and regulations. This includes compliance with the State Comptroller of Public Accounts' Reporting Requirements of State Agencies.

The Texas State Board of Pharmacy operates under the authority of Occupational Code Chapters 551-566 recodified September 1, 1999 from Tex. Rev. Civ. Stat. Ann. Art. 4542a-1.

*Due to the significant changes related to Governmental Accounting Standards Board Statement No. 34, Basic Financial Statements - and Management's Discussion and Analysis - for State and Local Governments, the Comptroller of Public Accounts does not require the accompanying financial report to be in compliance with generally accepted accounting principles (GAAP). The financial report will be considered for audit by the State Auditor as part of the State of Texas Comprehensive Annual Financial Report; therefore, an opinion has not been expressed on the financial statements and related information contained in this report.*

Blended Component Units

No component units have been identified that should have been blended into an appropriate fund.

B. FUND STRUCTURE

The accompanying financial statements are presented on the basis of funds and account groups, each of which is considered a separate accounting entity.

GOVERNMENTAL FUND TYPES & GOVERNMENT-WIDE ADJUSTMENT FUND TYPES

General Revenue Fund

The general revenue fund (fund 0001) is used to account for all financial resources of the state except those required to be accounted for in another fund.

Capital Asset Adjustment Fund Type

Capital Asset Adjustment Fund Type will be used to convert governmental fund types' capital assets from modified accrual to full accrual.

Long-Term Liabilities Adjustment Fund Type

Long-Term Liabilities Adjustment Fund Type will be used to convert governmental fund types' debt from modified accrual to full accrual.

FIDUCIARY FUND TYPES

Agency Funds

Agency funds are used to account for assets the government holds on behalf of others in a purely custodial capacity. Agency funds involve only the receipt, temporary investment, and remittance of fiduciary resources to individuals, private organizations, or other governments.

C. BASIS OF ACCOUNTING

The basis of accounting determines when revenues and expenditures or expenses are recognized in the accounts reported in the financial statements. The accounting and financial reporting treatment applied to a fund is determined by its measurement focus.

Governmental fund types that build the fund financial statements are accounted for using the

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
NOTES TO THE FINANCIAL STATEMENTS

modified accrual basis of accounting. Under the modified accrual, revenues are recognized in the period in which they become both measurable and available to finance operations of the fiscal year or liquidate liabilities existing at fiscal year end. The State of Texas considers receivables collected within sixty days after year-end to be available and recognizes them as revenues of the current year for Fund Financial Statements prepared on the modified basis of accrual. Expenditures and other uses of financial resources are recognized when the related liability is incurred.

Basis conversion adjustment fund types convert modified accrual basis to full accrual basis of accounting. The following activities are recognized in these fund types:

- \* Capital assets
- \* Accumulated depreciation
- \* Unpaid employee compensable leave
- \* The outstanding debt service principal on long-term liabilities
- \* Capital leases
- \* Long-term claims and judgements
- \* Full accrual revenues and expenses
- \* Pension amounts in governmental activities

Proprietary fund types and fiduciary fund types except agency funds are accounted for on the full accrual basis of accounting. Under the full accrual basis of accounting, revenues are recognized when earned and expenses are recognized at the time liabilities are incurred.

D. BUDGETS AND BUDGETARY ACCOUNTING

The budget is prepared biennially and represents appropriations authorized by the legislature and approved by the Governor (the General Appropriations Act).

Unencumbered appropriations are generally subject to lapse 60 days after the end of the fiscal year for which they were appropriated.

E. ASSETS, LIABILITIES, AND FUND BALANCES/NET POSITION

ASSETS

Cash and Cash Equivalents

Short-term highly liquid investments with an original maturity of three months or less are considered cash equivalents.

Restricted Assets

Restricted assets include monies or other resources restricted by legal or contractual requirements. These assets include proceeds of enterprise fund general obligation and revenue bonds and revenues set aside for statutory or contractual requirements.

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
NOTES TO THE FINANCIAL STATEMENTS

**Inventories & Prepaid Items**

Inventories include both merchandise inventories on hand for sale and consumable inventories. Inventories are valued at cost, generally utilizing the last-in, first-out method. Inventories for governmental fund types use the purchase method of accounting. The consumption method of accounting is used to account for inventories that appear in the proprietary fund types and the government-wide statements. The cost of these items is expensed when the items are consumed.

**Capital Assets**

Assets that meet the reporting threshold and useful life are capitalized. The capitalization threshold and the estimated useful life vary depending on the asset type. These assets are capitalized at cost, if purchased, or at appraised fair value as of the date of acquisition. Purchase of assets by governmental funds are reported as expenditures. Depreciation is reported on all "exhaustible" assets. "Inexhaustible" assets such as works of art and historical treasures are not depreciated. Road and highway infrastructure is depreciated over the estimate of average useful life of a grouping of assets using the composite method. Other depreciable assets are depreciated over the estimated useful life of the asset using the straight-line method.

All capital assets acquired by proprietary funds or trust funds are reported at cost or estimated historical cost, if actual historical cost is not available. Donated capital assets are reported at acquisition value. Depreciation is charged to operations over the estimated useful life of each asset, using the straight-line method.

**Other Receivables - Current and Noncurrent**

The disaggregation of other receivables as reported in the financial statements is disclosed in Note 24.

**LIABILITIES**

**Accounts Payable**

Accounts Payable represents the liability for the value of assets or services received at the balance sheet date for which payment is pending.

**Other Payables - Current and Noncurrent**

The disaggregation of other receivables as reported in the financial statements is disclosed in Note 24.

Employees' Compensable Leave

Employees' Compensable Leave Balances represent the liability that became "due" upon the occurrence of relevant events such as resignations, retirements, and uses of leave balances by covered employees. Liabilities are reported separately as either current or noncurrent in the statement of net assets.

FUND BALANCES/NET POSITION

"Fund balance" is the difference between assets plus deferred outflows of resources and liabilities plus deferred inflows of resources on the governmental fund statements. "Net position" is the difference between assets plus deferred outflows of resources and liabilities plus deferred inflows of resources on the government-wide, proprietary and fiduciary fund statements.

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
NOTES TO THE FINANCIAL STATEMENTS

The Board of Pharmacy uses resources in the following order:

\* When both restricted and unrestricted resources are available, use:

1. Restricted Resources
2. Unrestricted Resources (as they are needed)

\*When only unrestricted resources are available for use in governmental funds, use:

1. Committed Resources
2. Assigned Resources
3. Unassigned Resources

Fund Balance Components

Fund balances for governmental funds are classified as either nonspendable, restricted, committed, assigned or unassigned in the fund financial statements.

Nonspendable fund balance includes amounts not available to be spent because they are either: Not in spendable form -OR- Legally or contractually required to be maintained intact.

Restricted fund balance includes those resources that have constraints placed on their use through external parties - such as creditors, grantors, contributors, laws or regulations of other governments - or by law through constitutional provisions or enabling legislation.

Committed fund balance can be used only for specific purposes pursuant to constraints imposed through legislation passed into law by a formal action of the Texas Legislature, the state's highest level decision making authority.

Assigned fund balance includes amount constrained by the state's intent to be used for specific purposes, but the constraints do not meet the requirements to be reported as restricted or committed. Intent is expressed by: The Texas Legislature -OR- A body (for example, a budget or finance committee) or official to which the governing body has delegated the authority to assign amounts to be used for specific purposes.

Unassigned fund balance is the residual classification for the general fund. This classification represents fund balance that was not assigned to other funds and was not restricted, committed or assigned to specific purposes within the general fund.

Net Investment in Capital Assets

Net investment in capital assets, consists of capital assets, net of accumulated depreciation and reduced by outstanding balances for bond, notes and other debt that are attributed to the acquisition, construction, or improvement of those assets.

Restricted Net Position

Restricted Net Position results when constraints placed on net resources use are either externally imposed by creditors, grantors, contributors, and the like, or imposed by law through constitutional provisions or enabling legislation.

Unrestricted Net Position

Unrestricted Net Position consists of net resources, which do not meet the definition of the two preceding categories. Unrestricted net position often has constraints on resources, which are imposed by management, but can be removed or modified.

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
NOTES TO THE FINANCIAL STATEMENTS

F. INTERFUND TRANSACTIONS AND BALANCES

The agency has the following types of transactions among funds:

1) Transfers: Legally required transfers that are reported when incurred as "Transfers In" by the recipient fund and as "Transfers Out" by the disbursing fund.

2) Reimbursements: Reimbursements are repayments from funds responsible for expenditures or expenses to funds that made the actual payment. Reimbursements of expenditures made by one fund for another that are recorded as expenditures in the reimbursing fund and as a reduction of expenditures in the reimbursed fund.

3) Interfund receivables and payables: Interfund loans are reported as interfund receivables and payables. If repayment is due during the current year or soon thereafter it is classified as "Current", repayment for two (or more) years is classified as "Non-Current."

4) Interfund Sales and Purchases: Charges or collections for services rendered by one fund to another that are recorded as revenues of the recipient fund and expenditures or expenses of the disbursing fund. The composition of the agency's Interfund activities and transactions, if any, are presented in Note 12.

**NOTE 2: CAPITAL ASSETS**

A summary of changes in Capital Assets for the year ended August 31, 2024:

	Balance 9/01/23	Adjustments	Completed CIP	Reclassifications/ Inc Int'agy Trans	Reclassification: Dec Int'agy Trans
Governmental Activities:					
Depreciable Assets					
Furniture and					
Equipment	\$ 133,219.57	\$ 0.00	\$	\$ 0.00	\$ 0.00
Vehicles	628,260.59	0.00	0.00	0.00	0.00
Total depreciable assets	761,480.16	0.00	0.00	0.00	0.00
Less Accum Deprec for:					
Furniture and Equip	(75,035.08)				0.00
Vehicles	(420,459.95)	0.00			
Total Accum Deprec	(495,495.03)	0.00	0.00	0.00	0.00
Tot Deprec Assets Net	265,985.13	0.00	0.00	0.00	0.00
Intangible Assets					
Subscriptions	2,597,074.50				
Total Amortizable assets	2,597,074.50	0.00	0.00	0.00	0.00
Less Accum Amortiz:					
Subscriptions	(649,268.64)				
Total Accum Amort	(649,268.64)	0.00	0.00	0.00	0.00
Total Intang Asset Net	1,947,805.86	0.00	0.00	0.00	0.00
Total Governmtl Activ	\$ 2,213,790.99	\$ 0.00	\$ 0.00	\$ 0.00	\$ 0.00



UNAUDITED

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
NOTES TO THE FINANCIAL STATEMENTS

cont'd	<u>Addition</u>	<u>Deletions</u>	Balance <u>8/31/24</u>
Governmental Activities:			
Depreciable Assets			
Furniture and			
Equipment	\$ 0.00	\$ 0.00	\$ 133,219.57
Vehicles	<u>81,871.95</u>	<u>(53,356.37)</u>	<u>656,776.17</u>
Total depreciable assets	81,871.95	(53,356.37)	789,995.74
<b>Less Accum Deprec for:</b>			
Furniture and Equip	(12,454.08)		(87,489.16)
Vehicles	<u>(73,687.75)</u>	<u>53,356.37</u>	<u>(440,791.33)</u>
Total Accum Deprec	<u>(86,141.83)</u>	<u>53,356.37</u>	<u>(528,280.49)</u>
 Tot Deprec Assets Net	 <u>(4,269.88)</u>	 <u>0.00</u>	 <u>261,715.25</u>
 Intangible Assets			
Subscriptions			<u>2,597,074.50</u>
Total Amortizable assets	0.00	0.00	2,597,074.50
Less Accum Amortiz:			
Subscriptions	<u>(649,268.61)</u>		<u>(1,298,537.25)</u>
Total Accum Amort	<u>(649,268.61)</u>	<u>0.00</u>	<u>(1,298,537.25)</u>
 Total Intang Asset Net	 <u>(649,268.61)</u>	 <u>0.00</u>	 <u>1,298,537.25</u>
 Total Governmtl Activ	 <u>(653,538.49)</u>	 <u>0.00</u>	 <u>1,560,252.50</u>

**NOTE 3: DEPOSITS, INVESTMENTS & REPURCHASE AGREEMENTS**

Texas State Board of Pharmacy is authorized by statute to make investments following the "prudent person rule." There were no significant violations of legal provisions during the period.

Deposits of Cash in Bank

As of August 31, 2024, the carrying amount of deposits was \$15,000.00 as presented below.

Government Activities:

CASH IN BANK - CARRYING VALUE	\$ 15,000.00
Less: Certificates of Deposit included in carrying value and reported as Cash Equivalent	<u>0.00</u>
Cash in Bank per AFR	<u>\$ 15,000.00</u>
Governmental Funds Current Assets Cash in Bank	<u>\$ 15,000.00</u>
Cash in Bank per AFR	<u>\$ 15,017.64</u>

As of August 31, 2024, the total bank balances was as follows:

Governmental Activities	<u>\$ 15,000.00</u>
-------------------------	---------------------

None of the bank balances was exposed to custodial credit risk.

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
 NOTES TO THE FINANCIAL STATEMENTS

**NOTE 4: SHORT TERM DEBT**

Not applicable

**NOTE 5: SUMMARY OF LONG-TERM LIABILITIES**

Notes and Loans Payable:

The agency did not have any notes or loans payable as of August 31, 2024.

Changes In Long-Term Liabilities

During the year ended August 31, 2024, the following changes occurred in liabilities.

	Balance 9/01/23	Additions	Deductions	Balance 8/31/24	Amounts Due Within One Yr
Governmental Activities:					
Right to Use Subscptn	\$ 1,961,287.39	\$ 0.00	\$ 634,896.73	\$ 1,326,390.66	\$ 653,623.62
Compensable Leave	645,426.50	563,742.32	481,514.98	727,653.84	394,511.34
<b>TOTAL</b>	<b>\$ 2,606,713.89</b>	<b>\$ 563,742.32</b>	<b>\$ 1,116,411.71</b>	<b>\$ 2,054,044.50</b>	<b>\$ 1,048,134.96</b>

Employees' Compensable Leave

If a state employee had continuous employment with the state for at least six months, the state employee is entitled to be paid for all unused vacation time accrued in the event of the employee's resignation, dismissal or separation from state employment. Expenditures for accumulated annual leave balances are recognized in the period paid or taken in governmental fund types. For these fund types, the liability for unpaid benefits is recorded in the Statement of Net Position. Both an expense and liability for business-type activities are recorded in the proprietary funds as the benefits accrue to employees. No liability is recorded for non-vesting accumulating rights to receive sick pay benefits. This obligation is usually paid from the same funding source(s) from which the employee's salary or wage compensation was paid.

**NOTE 6: BONDED INDEBTEDNESS**

Not applicable

**NOTE 7: DERIVATIVE INSTRUMENTS**

Not applicable

**NOTE 8: LEASES/SBITAS**

Included in the expenditures reported in the financial statements are the following amounts of subscription fees paid under the noncancelable liability:

Fiscal Year 2024:

Fund Type	Amount
Governmental	\$684,999.99

Texas State Board of Pharmacy entered into an agreement for an IT subscription. This agreement commenced on September 1, 2022 and has 4 one year renewals through August 31, 2027.

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
 NOTES TO THE FINANCIAL STATEMENTS

Future Subscription Payments  
 Year Ended August 31, 2024

Year	Governmental Activity		Total
	Current Year Variable and Other	\$684,999.99 \$0.00	
	<u>Principal</u>	<u>Interest</u>	
2024	653,623.62	31,376.38	685,000.00
2025	672,767.04	12,232.96	685,000.00
2026			
2027			
2028			
2029-2033			
2034-2038			
2039-2043			
2044-2048			
2049-2053			
2054 and beyond			
TOTAL	\$ <u>1,326,390.66</u>	\$ <u>43,609.34</u>	\$ <u>1,370,000.00</u>

**NOTE 9: PENSION PLANS**

Not applicable

**NOTE 10: DEFERRED COMPENSATION**

Not applicable

**NOTE 11: POST EMPLOYMENT HEALTH CARE AND LIFE INSURANCE BENEFITS**

Not applicable

**NOTE 12: INTERFUND BALANCES/ACTIVITIES**

As explained in Note 1 on Interfund Transactions and Balances, there are numerous transactions between funds and agencies. At year end, amounts to be received or paid are reported as Interfund Receivables or Interfund Payables, Advances From or Advances To, or Due From or Due To Other Funds. Individual interfund receivable and payable balances at August 31, 2024 were as follows:

The agency experienced routine transfers with other state agencies, which were consistent with the activities of the fund making the transfer. Repayment of interfund balances will occur within one year from the date of the financial statement.

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
 NOTES TO THE FINANCIAL STATEMENTS

Individual balances and activities at August 31, 2024, follows:

	<u>Due From Other Agencies</u>	<u>Due To Other Agencies</u>
Governmental Funds (01)		
Appd Fund 0001, D23 Fund 1000		
Agency 507, D23 Fd 5150	8,706.00	
Agency 503, D23 Fd 1000	91,704.44	
Appd Fund 0001, D23 Fund 0001		
Agency 320, D23 Fd 0165		0.00
Total Due To/From	<u>\$ 100,410.44</u>	<u>\$ 0.00</u>
	<u>Operating Trfr In</u>	<u>Operating Trfr Out</u>
Governmental Funds (01)		
Appd Fund 0001, D23 Fund 0001		
Agency 902, D23 Fd 0001		165,914.93
Total Operating Transfers	<u>\$ 0.00</u>	<u>\$ 165,914.93</u>

**NOTE 13: CONTINUANCE SUBJECT TO REVIEW**

Under the Texas Sunset Act, the Agency will be abolished September 1, 2029, unless continued in existence by the State Legislature as provided by the Act. If abolished, the Agency may continue until September 1, 2030 to close out its operations.

**NOTE 14: ADJUSTMENTS TO FUND BALANCES/NET ASSETS**

Not applicable

**NOTE 15: CONTINGENCIES AND COMMITMENTS**

Not applicable

**NOTE 16: SUBSEQUENT EVENTS**

Not applicable

**NOTE 17: RISK MANAGEMENT**

Not applicable

**NOTE 18: MANAGEMENT DISCUSSION AND ANALYSIS/MATERIAL CHANGES TO AFR**

Not applicable

**NOTE 19: THE FINANCIAL REPORTING ENTITY: RELATED ORGANIZATIONS**

Not applicable

**NOTE 20: STEWARDSHIP, COMPLIANCE AND ACCOUNTABILITY**

Not applicable

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
NOTES TO THE FINANCIAL STATEMENTS

**NOTE 21: N/A**

**NOTE 22: DONOR-RESTRICTED ENDOWMENTS**

Not applicable

**NOTE 23: EXTRAORDINARY AND SPECIAL ITEMS**

Not applicable

**NOTE 24: DISAGGREGATION OF RECEIVABLE AND PAYABLE BALANCES**

Not applicable

**NOTE 25: TERMINATION BENEFITS**

Not applicable

**NOTE 26: SEGMENT INFORMATION**

Not applicable

**NOTE 27: SERVICE CONCESSION AGREEMENTS**

Not applicable

**NOTE 28: DEFERRED OUTFLOWS OF RESOURCES & DEFERRED INFLOWS OF RESOURCES**

Not applicable

**NOTE 29: TROUBLED DEBT RESTRUCTURING**

Not applicable

**NOTE 30: NON-EXCHANGE FINANCIAL GUARANTERS**

Not applicable

**NOTE 31: TAX ABATEMENTS**

Not applicable

**NOTE 32: FUND BALANCES**

Not applicable



UNAUDITED

GENERAL FUNDS Fund 0001 U/F (2882)	GENERAL FUNDS Fund 0001 U/F (8070)	TOTALS (EXHIBIT I) 2024
\$	\$	\$
		1,000.00
		15,000.00
	653.00	653.00
93,602.62		3,731,418.61
		8,706.00
		91,704.44
		0.00
\$ <u>93,602.62</u>	\$ <u>653.00</u>	\$ <u>3,848,482.05</u>
\$	\$	\$
<u>0.00</u>	<u>0.00</u>	<u>0.00</u>
<u>0.00</u>	<u>0.00</u>	<u>0.00</u>
\$ <u><u>93,602.62</u></u>	\$ <u><u>653.00</u></u>	\$ <u><u>3,848,482.05</u></u>
\$	\$	\$
		175,997.66
		0.00
	653.00	653.00
		96,598.04
		1,685,439.01
<u>0.00</u>	<u>653.00</u>	<u>1,958,687.71</u>
\$ <u>0.00</u>	\$ <u>653.00</u>	\$ <u>1,958,687.71</u>
\$	\$	\$
<u>93,602.62</u>	<u>0.00</u>	<u>0.00</u>
<u>93,602.62</u>	<u>0.00</u>	<u>1,889,794.34</u>
\$ <u><u>93,602.62</u></u>	\$ <u><u>653.00</u></u>	\$ <u><u>3,848,482.05</u></u>

UNAUDITED

TEXAS STATE BOARD OF PHARMACY (AGY 515)  
 EXHIBIT A-2  
 COMBINING STATEMENT OF REVENUES, EXPENDITURES & CHANGES IN  
 FUND BALANCES - GENERAL & CONSOLIDATED FUNDS  
 For the Year Ended August 31, 2024

	<u>GENERAL REVENUE FUND 0001 U/F (0001)</u>	<u>GENERAL REVENUE FUND 0001 U/F (1000)</u>
<b>REVENUES:</b>		
Legislative Appropriations	\$ 14,602,780.00	\$
Additional Appropriations	1,821,745.25	
Licenses, Fees and Permits	880,183.21	
Interest, Dividend and Other Income		
Other Revenue	<u>17,341.43</u>	
<b>Total Revenues</b>	<u>17,322,049.89</u>	<u>0.00</u>
<b>EXPENDITURES:</b>		
Salaries and Wages	7,066,187.83	
Payroll Related Costs	1,920,972.69	
Professional Fees & Services	4,362,296.73	
Travel	77,800.43	
Materials and Supplies	164,611.54	
Communication and Utilities	123,577.00	
Repairs and Maintenance	56,230.68	
Rentals and Leases	19,931.84	
Printing and Reproduction	166,360.77	
Other Operating Expenditures	465,025.64	
Debt Service Principal Leases/SBITA	634,896.73	
Capital Outlay	<u>81,871.95</u>	
<b>Total Expenditures</b>	<u>15,139,763.83</u>	<u>0.00</u>
<b>EXCESS OF REVENUES OVER EXPENDITURES</b>	<u>2,182,286.06</u>	<u>0.00</u>
<b>OTHER FINANCING SOURCES (USES):</b>		
Operating Transfers Out (Agy 902, Fund 0001)	(165,914.93)	
Sale of Vehicle	10,133.93	
Increase in Obligations - Leases/ SBITA		
Legislative Transfers Out (Agy 364, Fd 0001)	<u>(485,420.00)</u>	
<b>Total Other Financing Sources (Uses)</b>	<u>(641,201.00)</u>	<u>0.00</u>
<b>EXCESS OF REVENUE &amp; OTHER FINANCING SOURCES OVER EXPENDITURES &amp; OTHER FINANCING USES</b>	<u>1,541,085.06</u>	<u>0.00</u>
<b>FUND BALANCES - Beginning</b>	785,755.57	3,812.40
Restatements	0.00	
<b>Fund Balances Beginning Restated</b>	<u>785,755.57</u>	<u>3,812.40</u>
Lapsed Appropriations	<u>(534,461.31)</u>	<u>0.00</u>
<b>FUND BALANCES - Ending</b>	<u>\$ 1,792,379.32</u>	<u>\$ 3,812.40</u>

The accompanying notes to the financial statements are an integral part of this financial statements.



UNAUDITED

GENERAL REVENUE FUND 0001 U/F (2782)	GENERAL REVENUE FUND 0001 U/F (2882)	TOTALS EXHIBIT II 2024
\$	\$	\$ 14,602,780.00
		1,821,745.25
		880,183.21
		0.00
(93,327.06)	93,602.62	17,616.99
(93,327.06)	93,602.62	17,322,325.45
		7,066,187.83
		1,920,972.69
		4,362,296.73
		77,800.43
		164,611.54
		123,577.00
		56,230.68
		19,931.84
		166,360.77
		465,025.64
		634,896.73
		81,871.95
0.00	0.00	15,139,763.83
(93,327.06)	93,602.62	2,182,561.62
		(165,914.93)
		10,133.93
		0.00
		(485,420.00)
0.00	0.00	(641,201.00)
(93,327.06)	93,602.62	1,541,360.62
93,327.06	0.00	882,895.03
93,327.06	0.00	882,895.03
0.00	0.00	(534,461.31)
\$ 0.00	\$ 93,602.62	\$ 1,889,794.34